Sunday, April 20, 2025

ICU Sleep Hygiene

ICU Sleep Hygiene: Current Evidence and Practical Interventions

Dr Neeraj Manikath, claude.ai

Abstract

Sleep disruption is ubiquitous in intensive care units (ICUs) and contributes significantly to patient morbidity, delirium incidence, and potentially worse clinical outcomes. This review synthesizes current evidence regarding sleep architecture alterations in critically ill patients, discusses the multifaceted etiology of ICU sleep disruption, evaluates sleep assessment methods applicable to the critical care setting, and examines evidence-based interventions to improve sleep in the ICU. The implementation of ICU sleep hygiene protocols requires a multidisciplinary approach combining environmental modifications, pharmacologic optimization, and organizational changes. Recent evidence suggests that bundled interventions targeting multiple sleep disruptors may provide the most substantial benefit. We present practical recommendations for implementing sleep promotion strategies in critical care units based on the best available evidence, while acknowledging limitations in current research and highlighting priorities for future investigation.

Keywords: Sleep hygiene, intensive care unit, sleep disruption, delirium, environmental noise, light exposure, sleep bundle, critical care

Introduction

Sleep is fundamentally disrupted in critically ill patients. Studies consistently demonstrate significant alterations in sleep architecture and quality among ICU patients, with potential ramifications for recovery, cognitive function, immune response, and mortality.^1,2^ Normal sleep consists of cyclical patterns alternating between non-rapid eye movement (NREM) stages (N1, N2, and N3) and rapid eye movement (REM) sleep. In critically ill patients, sleep is characterized by severe fragmentation, abnormal sleep architecture with predominance of light sleep (N1 and N2), reduction or absence of restorative slow-wave (N3) and REM sleep, and altered circadian rhythmicity.^3,4^ These disruptions persist even after controlling for severity of illness and may continue beyond the ICU stay, with potential long-term consequences.^5^

Studies have reported that ICU patients experience 40-60 awakenings per hour, with normal sleep consolidation largely absent.^6^ Critically ill patients rarely complete full sleep cycles, with a preponderance of brief sleep fragments rather than consolidated sleep periods. These abnormalities have been associated with higher rates of delirium, prolonged mechanical ventilation, increased length of ICU stay, and potentially worse long-term outcomes.^7,8^

This review examines the current evidence regarding ICU sleep disruption, measurement techniques, and interventions aimed at improving sleep hygiene in critical care environments. We provide evidence-based recommendations for implementation of sleep hygiene protocols to optimize recovery and outcomes in critically ill patients.

Sleep Architecture and Its Disruption in Critical Illness

Normal Sleep Architecture

Normal sleep in healthy adults follows a predictable pattern of 90-120 minute cycles, each comprising NREM sleep (stages N1, N2, N3) followed by REM sleep. N3 (slow-wave sleep) predominates during the first third of the night and is associated with physical restoration, while REM sleep increases in the latter portion of the night and is linked to cognitive function and memory consolidation.^9^ These cycles are regulated by the interaction between homeostatic sleep pressure (which increases with wakefulness) and circadian rhythms (primarily influenced by light exposure).^10^

Sleep Architecture in Critical Illness

Polysomnographic studies in ICU patients reveal profound alterations to this normal architecture:^11,12^

Severe fragmentation: Frequent arousals and awakenings, with sleep efficiency reduced to 40-60% (vs. >85% in healthy adults)
Altered sleep stage distribution: Predominance of light sleep (stages N1 and N2, up to 90% of total sleep time)
Reduction or absence of restorative sleep: Decreased N3 (slow-wave) sleep and REM sleep (each <5% of total sleep time, compared to 20-25% in healthy adults)
Circadian rhythm disruption: Loss of day-night sleep consolidation, with 40-50% of total sleep occurring during daytime hours
Atypical sleep patterns: Presence of atypical sleep patterns that do not conform to standard sleep staging, particularly in patients with sepsis or delirium

These disruptions manifest even in the absence of sedative medications, though certain sedatives (particularly benzodiazepines) further suppress N3 and REM sleep.^13^ Critically, these alterations persist beyond the ICU stay and may contribute to post-intensive care syndrome (PICS).^14^

Etiology of Sleep Disruption in ICU

Sleep disruption in the ICU is multifactorial, involving patient-related, environmental, iatrogenic, and treatment-related factors. Understanding these mechanisms is essential for developing targeted interventions.

Environmental Factors

Noise

Environmental noise is a predominant cause of sleep disruption, with ICU sound levels consistently exceeding World Health Organization recommendations (average 45-65 dB, with peaks up to 80-90 dB, vs. recommended <30 dB).^15,16^ Sources include:

Equipment alarms (bedside monitors, ventilators, infusion pumps)
Staff conversations (particularly at shift changes)
Clinical activities and procedures
Telephones and intercoms
Door closures and equipment movement

Studies using polysomnography with synchronous environmental monitoring have demonstrated direct correlations between noise peaks and sleep arousals, with 11-17% of awakenings directly attributable to noise.^17^ Critically, the unpredictable and variable nature of ICU noise may be more disruptive than absolute sound levels.

Light

Inappropriate light exposure disrupts melatonin production and circadian rhythmicity, which are fundamental to normal sleep-wake cycles.^18,19^ ICU environments frequently maintain inappropriate light levels:

Excessive light during nighttime (from monitoring equipment, corridor lighting, and procedural lighting)
Insufficient bright light exposure during daytime
Unpredictable light variations throughout the 24-hour cycle

Studies measuring light levels in ICUs have found nighttime illumination often exceeds 100 lux, well above the <10 lux threshold for melatonin suppression.^20^ This contributes to the flattened circadian rhythm observed in ICU patients through suppression of melatonin production.

Patient-Related Factors

Intrinsic patient factors contributing to sleep disruption include:

Illness severity: Critical illness itself affects sleep architecture, with more severe illness associated with greater sleep fragmentation^21^
Pain and discomfort: Uncontrolled pain is a significant cause of sleep disruption, with studies showing strong negative correlations between pain scores and sleep quality^22^
Psychological distress: Anxiety, stress, and depression are prevalent in ICU patients and adversely affect sleep^23^
Medical conditions: Certain conditions directly impact sleep, including respiratory disorders, heart failure, and neurological conditions^24^
Pre-existing sleep disorders: Undiagnosed or untreated sleep-disordered breathing may worsen during critical illness^25^

Iatrogenic and Treatment-Related Factors

Medical interventions paradoxically contribute to sleep disruption:

Patient Care Activities

Studies using time-motion analysis have documented that ICU patients experience 40-60 interactions per night, with clustering during sleep-conducive hours.^26,27^ Watson et al. found that patient care activities accounted for 7-25% of sleep disruptions in medical ICU patients.^28^ These include:

Vital sign measurements
Medication administration
Phlebotomy and laboratory collections
Physical examinations
Radiographic procedures
Bathing and position changes

Mechanical Ventilation

Mechanical ventilation profoundly affects sleep quality through multiple mechanisms:^29,30^

Patient-ventilator asynchrony
Inappropriate ventilator settings causing central apneas
Discomfort from endotracheal tubes
Air leaks triggering frequent alarms
Inability to communicate discomfort

Studies comparing ventilator modes suggest that modes with fixed backup rates (e.g., assist-control) may preserve sleep better than modes requiring more patient effort (e.g., pressure support).^31,32^

Medications

Numerous medications commonly used in the ICU adversely affect sleep architecture:^33,34^

Sedatives: While inducing unconsciousness, many sedatives (particularly benzodiazepines) suppress REM and N3 sleep
Opioids: Reduce REM and slow-wave sleep
Vasopressors: Beta-adrenergic agents suppress melatonin and disrupt normal sleep architecture
Corticosteroids: Suppress REM sleep and fragment sleep patterns
Antibiotics: Some classes (fluoroquinolones) have CNS effects that may impact sleep quality

Conversely, abrupt discontinuation of sedatives can cause rebound sleep disruption and withdrawal phenomena.^35^

Sleep Assessment in the ICU

Accurate assessment of sleep in critically ill patients poses significant challenges. Available methods include:

Polysomnography (PSG)

PSG remains the gold standard for sleep assessment but presents logistical challenges in the ICU:^36,37^

Advantages: Provides objective, detailed data on sleep architecture and quality
Limitations:
- Resource-intensive and expensive
- Requires specialized interpretation
- May interfere with clinical care
- Standard scoring criteria may not apply to critically ill patients due to abnormal EEG patterns
- Typically limited to research settings

Bispectral Index (BIS) and Other Processed EEG

Simplified EEG-based monitoring systems offer potential alternatives:^38,39^

Advantages: Less intrusive than full PSG, continuous monitoring capability
Limitations:
- Primarily validated for anesthetic depth, not sleep architecture
- Unable to differentiate specific sleep stages reliably
- Affected by neuromuscular blockade and certain neurological conditions

Actigraphy

Actigraphy uses wrist-worn accelerometers to estimate sleep-wake cycles based on movement:^40,41^

Advantages: Non-invasive, continuous monitoring over extended periods
Limitations:
- May overestimate sleep in critically ill patients with limited mobility
- Cannot assess sleep architecture or quality
- Accuracy affected by passive movements (e.g., during patient care)

Subjective Assessments

Validated sleep questionnaires include:^42,43^

Richards-Campbell Sleep Questionnaire (RCSQ)
Pittsburgh Sleep Quality Index (PSQI)
Verran and Snyder-Halpern Sleep Scale
Sleep in Intensive Care Questionnaire
Advantages: Quick, non-invasive, capture patient experience
Limitations:
- Require patient cooperation and intact cognition
- Subject to recall bias
- Not applicable to sedated or delirious patients
- Poor correlation with objective measures in some studies

Nurse Observation

Nurse assessment of patient sleep:^44^

Advantages: Non-invasive, routinely available
Limitations:
- Poor correlation with PSG, particularly overestimating sleep time
- Unable to detect sleep fragmentation or stages
- Impractical for continuous monitoring

Current evidence suggests that a multimodal approach combining subjective and objective measurements may provide the most comprehensive assessment of sleep in ICU patients who are sufficiently alert to participate.^45^

Consequences of Sleep Disruption in Critical Illness

Sleep disruption in critically ill patients is associated with numerous adverse physiological and psychological consequences:

Neuropsychiatric Effects

Delirium

The relationship between sleep disruption and delirium is bidirectional and complex. Systematic reviews and meta-analyses have demonstrated strong associations between sleep disruption and subsequent delirium development, with relative risks ranging from 1.8 to 3.2.^46,47^ Mechanisms include:

Shared neuroinflammatory pathways
Disruption of sleep-dependent neuronal recovery processes
Neurotransmitter imbalances affecting both sleep and cognition
Circadian rhythm disruption

Kamdar et al. demonstrated that implementation of a sleep-promotion protocol was associated with decreased delirium incidence (odds ratio 0.46, 95% CI 0.23-0.89) and fewer days with delirium in medical ICU patients.^48^

Cognitive Function

Sleep disruption impairs multiple cognitive domains relevant to recovery:^49,50^

Attention and concentration
Memory formation and consolidation
Executive function
Processing speed
Decision-making capacity

These impairments may persist after ICU discharge and contribute to the cognitive component of post-intensive care syndrome.^51^

Immune Function

Sleep plays a crucial role in immune regulation, with disruption leading to:^52,53^

Altered cytokine production (increased pro-inflammatory cytokines)
Reduced natural killer cell activity
Impaired antibody response
Altered leukocyte trafficking
Dysregulated hypothalamic-pituitary-adrenal axis

These changes may theoretically increase susceptibility to infections and impair recovery from critical illness, though direct evidence in ICU populations remains limited.^54^

Cardiovascular Effects

Sleep disruption impacts cardiovascular function through:^55,56^

Increased sympathetic activity
Elevated blood pressure
Impaired glucose tolerance
Increased inflammatory markers
Endothelial dysfunction

These effects may be particularly relevant in patients with pre-existing cardiovascular disease.

Respiratory Effects

Sleep fragmentation impairs respiratory function via:^57,58^

Decreased respiratory muscle endurance
Altered ventilatory responses
Increased work of breathing
Worsening of sleep-disordered breathing

These changes may complicate weaning from mechanical ventilation.^59^

Metabolic Effects

Sleep disruption adversely affects metabolism through:^60,61^

Altered glucose metabolism and insulin resistance
Disrupted appetite regulation
Altered hormonal milieu (leptin, ghrelin)
Dysregulated cortisol secretion

These changes may impact nutritional status and recovery.

Clinical Outcomes

While associations between sleep disruption and hard clinical outcomes remain an area of active investigation, several studies suggest potential relationships with:^62,63,64^

Increased ICU and hospital length of stay
Prolonged mechanical ventilation
Decreased ventilator-free days
Higher mortality in certain subgroups
Increased post-ICU psychiatric morbidity

However, causality remains difficult to establish, as sleep disruption may be both a cause and consequence of greater illness severity.

Interventions to Improve Sleep in the ICU

Evidence-based interventions for improving ICU sleep hygiene can be categorized into environmental modifications, pharmacological approaches, and non-pharmacological strategies.

Environmental Modifications

Noise Reduction Strategies

Multiple studies have evaluated noise reduction interventions:^65,66,67^

Alarm management protocols: Individualizing alarm parameters, eliminating redundant alarms, and setting appropriate thresholds
Sound-absorbing materials: Acoustic ceiling tiles, wall panels, and curtains
Equipment modification: Selection of quieter equipment and regular maintenance
Staff education: Awareness of conversation volume, silencing telephones and pagers during sleep periods
Earplugs: Multiple randomized controlled trials have demonstrated efficacy, with a meta-analysis showing reduced delirium risk (RR 0.59, 95% CI 0.44-0.78)^68^
Sound masking: White noise or ambient sound generators to reduce perceived noise fluctuations

Interventions targeting behavior change among staff have shown particular promise, with reductions in peak noise levels of 6-10 dB when implemented comprehensively.^69^

Light Optimization

Evidence supports the following interventions:^70,71,72^

Dynamic lighting systems: Programmable systems that mimic natural circadian patterns
Nighttime light reduction: Eye masks, dimmed lights, and minimal use of procedural lighting
Daytime light exposure: Natural sunlight or high-intensity light therapy (>1000 lux) during morning hours
Timed light exposure: Strategic exposure to bright light in morning hours to entrain circadian rhythms

A randomized controlled trial by Simons et al. found that dynamic lighting improved subjective sleep quality and reduced delirium incidence by 45%.^73^

Non-Pharmacological Interventions

Patient Comfort Optimization

Pain management: Protocolized pain assessment and treatment, with specific attention to nighttime analgesia needs^74^
Positioning: Optimizing patient comfort through proper positioning and pressure relief^75^
Temperature regulation: Maintaining comfortable ambient temperatures (typically 22-24°C) and providing warming or cooling as needed^76^

Clustering Care Activities

Strategic timing and organization of care activities can reduce sleep fragmentation:^77,78^

Consolidating routine assessments and interventions
Creating protected sleep periods with minimal non-urgent interventions
Coordinating care across disciplines to minimize disruptions
Adjusting medication administration schedules to minimize nighttime disruptions

Quiet time protocols implementing 2-3 hour periods of minimized disruptions have been associated with improved sleep efficiency and subjective sleep quality.^79^

Mechanical Ventilation Optimization

Evidence supports the following approaches:^80,81^

Addressing patient-ventilator asynchrony
Selecting ventilator modes that minimize sleep disruption (often pressure assist-control)
Avoiding auto-PEEP and addressing air leaks
Minimizing unnecessary alarms
Optimization of ventilator settings during sleep periods

Relaxation Techniques

Multiple relaxation modalities have shown benefit:^82,83^

Music therapy: Structured music interventions before sleep periods
Massage: Brief massage therapy to reduce muscle tension
Guided imagery and relaxation: Recorded or guided relaxation exercises
Meditation and mindfulness: Simple meditation techniques adapted for critically ill patients

A 2018 systematic review found positive effects on sleep quality with standardized relaxation interventions (standardized mean difference 0.61, 95% CI 0.38-0.85).^84^

Pharmacological Interventions

Evidence regarding pharmacological sleep aids in ICU patients is limited and conflicting:

Melatonin and Melatonin Receptor Agonists

Melatonin: Evidence from small RCTs suggests modest benefits for sleep quality, with minimal side effects (typical doses 3-10 mg)^85,86^
Ramelteon: Limited data in ICU populations, but may preserve better sleep architecture than benzodiazepines^87^

However, a 2018 systematic review found inconsistent effects of melatonin on sleep quality and delirium prevention in critically ill patients.^88^

Sedative-Hypnotics

Current evidence does not support routine use of traditional hypnotics:^89,90^

Benzodiazepines: Disrupt sleep architecture, suppress REM sleep, and may increase delirium risk
Non-benzodiazepine hypnotics (Z-drugs): Limited evidence in ICU setting, but may have fewer adverse effects than benzodiazepines
Dexmedetomidine: Preserves sleep architecture better than benzodiazepines and may have delirium-sparing effects, but evidence for routine use as a sleep aid is limited

Antipsychotics and Antidepressants

Antipsychotics: Limited evidence for sleep promotion, though commonly used off-label^91^
Trazodone and other sedating antidepressants: Insufficient evidence in ICU populations^92^

Current guidelines recommend minimizing sedative-hypnotic medications when possible and using non-pharmacological approaches as first-line therapy.^93^

Multicomponent "Sleep Hygiene" Bundles

Growing evidence supports bundled interventions that simultaneously address multiple sleep disruptors:^94,95,96^

Typical components include:

Environmental modifications (noise reduction, light control)
Non-pharmacological interventions (clustering care, comfort measures)
Pharmacological optimization (minimizing sleep-disrupting medications)
Staff education and protocol implementation

Studies implementing comprehensive sleep promotion bundles have demonstrated improvements in:

Subjective sleep quality
Delirium incidence and duration
ICU length of stay
Patient satisfaction

A landmark study by Patel et al. demonstrated that implementation of a multifaceted sleep-promotion protocol reduced delirium incidence by 33% and improved hospital mortality (odds ratio 0.63, 95% CI 0.42-0.91).^97^

Implementation Strategies and Practical Considerations

Successful implementation of sleep hygiene protocols in the ICU requires a structured approach:

Multidisciplinary Team Approach

Evidence supports the involvement of:^98,99^

Physicians (intensivists, specialists)
Nurses (bedside and advanced practice)
Respiratory therapists
Pharmacists
Physical and occupational therapists
Environmental services

Education and Staff Engagement

Successful programs incorporate:^100,101^

Staff education regarding sleep physiology and importance
Regular feedback on protocol adherence
Identification of unit champions
Involvement of frontline staff in protocol development
Addressing barriers to implementation

Protocol Development

Effective protocols typically include:^102,103^

Clear delineation of roles and responsibilities
Specific environmental modifications
Dedicated quiet time periods
Standardized assessment tools
Decision support for pharmacological interventions
Metrics for monitoring compliance and outcomes

Quality Improvement Framework

Implementing sleep hygiene interventions within a quality improvement framework enhances success:^104,105^

Baseline measurement of sleep quality and disruptions
Setting specific, measurable improvement goals
Plan-Do-Study-Act cycles for protocol refinement
Regular monitoring of compliance and outcomes
Sustainability planning

Patient and Family Engagement

Incorporating patients and families improves outcomes:^106,107^

Education about sleep importance during critical illness
Involvement in daily planning to accommodate sleep periods
Encouraging family participation in non-pharmacological interventions
Soliciting feedback on sleep quality and barriers

Barriers and Challenges

Implementation of sleep hygiene protocols faces several challenges:^108,109^

Competing clinical priorities in acute care settings
Resistance to change in established workflow patterns
Resource limitations (staffing, equipment modifications)
Difficulty balancing sleep promotion with necessary monitoring and interventions
Varying levels of evidence for specific interventions
Measurement challenges in assessing sleep quality

Practical Recommendations

Based on current evidence, we propose the following practical recommendations for ICU sleep hygiene implementation:

Essential Elements of an ICU Sleep Protocol

Environmental modifications:
- Reduce nighttime noise levels (target <45 dB)
- Dim lights during sleep periods (<20 lux)
- Provide earplugs and eye masks to eligible patients
- Ensure appropriate temperature regulation (22-24°C)
Scheduled quiet periods:
- Designate 2-hour periods (typically 2:00-4:00 AM and 2:00-4:00 PM) with minimal non-urgent interventions
- Cluster necessary care activities outside these periods
- Close doors when possible during quiet periods
- Reduce staff conversation volume and minimize alarm sounds
Patient comfort optimization:
- Regular assessment and management of pain
- Attention to positioning and pressure relief
- Management of thirst and oral hygiene
- Address anxiety through appropriate interventions
Ventilator optimization:
- Ensure appropriate mode selection
- Minimize unnecessary alarms
- Address patient-ventilator asynchrony
Pharmacological considerations:
- Review and minimize sleep-disrupting medications
- Consider melatonin (3-10 mg) for select patients
- Avoid benzodiazepines when possible
- Time medication administration to minimize sleep disruption
Daytime interventions:
- Maximize daytime light exposure
- Encourage physical activity when appropriate
- Minimize daytime napping when possible
- Promote normal day-night distinction
Individualized approaches:
- Assess and accommodate pre-existing sleep patterns
- Consider patient preferences for sleep environment
- Modify approaches based on cognitive status and illness severity

Implementation Process

Form a multidisciplinary sleep promotion team
Conduct baseline sleep quality assessment
Develop unit-specific protocol incorporating evidence-based elements
Educate all staff on sleep physiology and protocol components
Implement protocol using a phased approach
Monitor compliance and outcomes
Refine protocol based on feedback and outcomes
Develop sustainability plan for long-term implementation

Future Directions

Several areas warrant further investigation:

Validation of sleep assessment tools specifically designed for critically ill patients
Comparative effectiveness studies of different bundled interventions
Pharmacological studies with sleep architecture endpoints rather than subjective measures
Long-term outcome studies examining the impact of ICU sleep quality on post-discharge outcomes
Personalized approaches to sleep promotion based on patient characteristics
Technology integration for continuous monitoring and intervention adjustment
Economic analyses of sleep promotion interventions and potential cost savings

Conclusion

Sleep disruption in ICU patients is a modifiable risk factor with significant implications for patient outcomes. Current evidence supports a multimodal approach combining environmental modifications, non-pharmacological interventions, and judicious use of pharmacological agents. Implementation of structured sleep hygiene protocols using quality improvement methodology shows promise for improving sleep quality, reducing delirium, and potentially improving clinical outcomes in critically ill patients. While challenges remain in assessment and implementation, sleep promotion should be considered an essential component of comprehensive critical care.

References

Pisani MA, Friese RS, Gehlbach BK, et al. Sleep in the intensive care unit. Am J Respir Crit Care Med. 2015;191(7):731-738. doi:10.1164/rccm.201411-2099CI
Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9)
. doi:10.1097/CCM.0000000000003299
Freedman NS, Gazendam J, Levan L, et al. Abnormal sleep/wake cycles and the effect of environmental noise on sleep disruption in the intensive care unit. Am J Respir Crit Care Med. 2001;163(2):451-457. doi:10.1164/ajrccm.163.2.9912128
Elliott R, McKinley S, Cistulli P, et al. Characterisation of sleep in intensive care using 24-hour polysomnography: an observational study. Crit Care. 2013;17(2)
. doi:10.1186/cc12565
Altman MT, Knauert MP, Pisani MA. Sleep disturbance after hospitalization and critical illness: a systematic review. Ann Am Thorac Soc. 2017;14(9):1457-1468. doi:10.1513/AnnalsATS.201702-148SR
Boyko Y, Ording H, Jennum P. Sleep disturbances in critically ill patients in ICU: how much do we know? Acta Anaesthesiol Scand. 2012;56(8):950-958. doi:10.1111/j.1399-6576.2012.02672.x
Kamdar BB, Needham DM, Collop NA. Sleep deprivation in critical illness: its role in physical and psychological recovery. J Intensive Care Med. 2012;27(2):97-111. doi:10.1177/0885066610394322
Salluh JI, Wang H, Schneider EB, et al. Outcome of delirium in critically ill patients: systematic review and meta-analysis. BMJ. 2015;350
. doi:10.1136/bmj.h2538
Carskadon MA, Dement WC. Normal human sleep: an overview. In: Kryger M, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 6th ed. Elsevier; 2017:15-24.
Czeisler CA, Buxton OM. The human circadian timing system and sleep-wake regulation. In: Kryger M, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 6th ed. Elsevier; 2017:362-376.
Cooper AB, Thornley KS, Young GB, et al. Sleep in critically ill patients requiring mechanical ventilation. Chest. 2000;117(3):809-818. doi:10.1378/chest.117.3.809
Drouot X, Cabello B, d'Ortho MP, et al. Sleep in the intensive care unit. Sleep Med Rev. 2008;12(5):391-403. doi:10.1016/j.smrv.2007.11.004
Oto J, Yamamoto K, Koike S, et al. Effect of daily sedative interruption on sleep stages of mechanically ventilated patients receiving midazolam by infusion: a pilot study. Anaesth Intensive Care. 2011;39(3):392-400. doi:10.1177/0310057X1103900310
Demoule A, Carreira S, Lavault S, et al. Impact of earplugs and eye mask on sleep in critically ill patients: a prospective randomized study. Crit Care. 2017;21(1):284. doi:10.1186/s13054-017-1865-0
Darbyshire JL, Young JD. An investigation of sound levels on intensive care units with reference to the WHO guidelines. Crit Care. 2013;17(5)
. doi:10.1186/cc12870
Buxton OM, Ellenbogen JM, Wang W, et al. Sleep disruption due to hospital noises: a prospective evaluation. Ann Intern Med. 2012;157(3):170-179. doi:10.7326/0003-4819-157-3-201208070-00472
Gabor JY, Cooper AB, Crombach SA, et al. Contribution of the intensive care unit environment to sleep disruption in mechanically ventilated patients and healthy subjects. Am J Respir Crit Care Med. 2003;167(5):708-715. doi:10.1164/rccm.2201090
Perras B, Meier M, Dodt C. Light and darkness fail to regulate melatonin release in critically ill humans. Intensive Care Med. 2007;33(11):1954-1958. doi:10.1007/s00134-007-0769-x
Durrington HJ, Clark R, Greer R, et al. 'In a dark place, we find ourselves': light intensity in critical care units. Intensive Care Med Exp. 2017;5(1):9. doi:10.1186/s40635-017-0122-9
Verceles AC, Silhan L, Terrin M, et al. Circadian rhythm disruption in severe sepsis: the effect of ambient light on urinary 6-sulfatoxymelatonin secretion. Intensive Care Med. 2012;38(5):804-810. doi:10.1007/s00134-012-2494-3
Friese RS, Bruns B, Sinton CM. Sleep deprivation after septic insult increases mortality independent of age. J Trauma. 2009;66(1):50-54. doi:10.1097/TA.0b013e318190c3a1
Kamdar BB, Shah PA, King LM, et al. Patient-nurse interrater reliability and agreement of the Richards-Campbell Sleep Questionnaire. Am J Crit Care. 2012;21(4):261-269. doi:10.4037/ajcc2012111
Rotondi AJ, Chelluri L, Sirio C, et al. Patients' recollections of stressful experiences while receiving prolonged mechanical ventilation in an intensive care unit. Crit Care Med. 2002;30(4):746-752. doi:10.1097/00003246-200204000-00004
Maldonado JR. Neuropathogenesis of delirium: review of current etiologic theories and common pathways. Am J Geriatr Psychiatry. 2013;21(12):1190-1222. doi:10.1016/j.jagp.2013.09.005
Knauert MP, Yaggi HK, Redeker NS, et al. Feasibility study of unattended polysomnography in medical intensive care unit patients. Heart Lung. 2014;43(5):445-452. doi:10.1016/j.hrtlng.2014.06.049
Tamburri LM, DiBrienza R, Zozula R, et al. Nocturnal care interactions with patients in critical care units. Am J Crit Care. 2004;13(2):102-112.
Le A, Friese RS, Hsu CH, et al. Sleep disruptions and nocturnal nursing interactions in the intensive care unit. J Surg Res. 2012;177(2):310-314. doi:10.1016/j.jss.2012.05.038
Watson PL, Pandharipande P, Gehlbach BK, et al. Atypical sleep in ventilated patients: empirical electroencephalography findings and the path toward revised ICU sleep scoring criteria. Crit Care Med. 2013;41(8):1958-1967. doi:10.1097/CCM.
Cabello B, Thille AW, Drouot X, et al. Sleep quality in mechanically ventilated patients: comparison of three ventilatory modes. Crit Care Med. 2008;36(6):1749-1755. doi:10.1097/CCM.0b013e3181743f41
Delisle S, Ouellet P, Bellemare P, et al. Sleep quality in mechanically ventilated patients: comparison between NAVA and PSV modes. Ann Intensive Care. 2011;1(1):42. doi:10.1186/2110-5820-1-42
Parthasarathy S, Tobin MJ. Effect of ventilator mode on sleep quality in critically ill patients. Am J Respir Crit Care Med. 2002;166(11):1423-1429. doi:10.1164/rccm.200209-999OC
Bosma K, Ferreyra G, Ambrogio C, et al. Patient-ventilator interaction and sleep in mechanically ventilated patients: pressure support versus proportional assist ventilation. Crit Care Med. 2007;35(4):1048-1054. doi:10.1097/01.CCM.0000260055.64235.7C
Trompeo AC, Vidi Y, Locane MD, et al. Sleep disturbances in the critically ill patients: role of delirium and sedative agents. Minerva Anestesiol. 2011;77(6):604-612.
Bourne RS, Mills GH. Sleep disruption in critically ill patients--pharmacological considerations. Anaesthesia. 2004;59(4):374-384. doi:10.1111/j.1365-2044.2004.03664.x
Weinhouse GL, Watson PL. Sedation and sleep disturbances in the ICU. Crit Care Clin. 2009;25(3):539-549. doi:10.1016/j.ccc.2009.04.003
Roche Campo F, Drouot X, Thille AW, et al. Poor sleep quality is associated with late noninvasive ventilation failure in patients with acute hypercapnic respiratory failure. Crit Care Med. 2010;38(2):477-485. doi:10.1097/CCM.0b013e3181bc8243
Knauert MP, Malik V, Kamdar BB. Sleep and sleep disordered breathing in hospitalized patients. Semin Respir Crit Care Med. 2014;35(5):582-592. doi:10.1055/s-0034-1395823
Nieuwenhuijs D, Coleman EL, Douglas NJ, et al. Bispectral index values and spectral edge frequency at different stages of physiologic sleep. Anesth Analg. 2002;94(1):125-129. doi:10.1097/00000539-200201000-00024
Giménez S, Romero S, Alonso JF, et al. Monitoring sleep depth: analysis of bispectral index (BIS) based on polysomnographic recordings and sleep deprivation. J Clin Monit Comput. 2017;31(1):103-110. doi:10.1007/s10877-015-9805-5
Beecroft JM, Ward M, Younes M, et al. Sleep monitoring in the intensive care unit: comparison of nurse assessment, actigraphy and polysomnography. Intensive Care Med. 2008;34(11):2076-2083. doi:10.1007/s00134-008-1180-y
Schwab KE, Ronish B, Needham DM, et al. Actigraphy to evaluate sleep in the intensive care unit. A systematic review. Ann Am Thorac Soc. 2018;15(9):1075-1082. doi:10.1513/AnnalsATS.201801-004OC
Richards KC, O'Sullivan PS, Phillips RL. Measurement of sleep in critically ill patients. J Nurs Meas. 2000;8(2):131-144. doi:10.1891/1061-3749.8.2.131
Ritmala-Castren M, Lakanmaa RL, Virtanen I, et al. Evaluating adult patients' sleep: an integrative literature review in critical care. Scand J Caring Sci. 2014;28(3):435-448. doi:10.1111/scs.12072
Edwards GB, Schuring LM. Pilot study: validating staff nurses' observations of sleep and wake states among critically ill patients, using polysomnography. Am J Crit Care. 1993;2(2):125-131. doi:10.4037/ajcc1993.2.2.125
Kamdar BB, King LM, Collop NA, et al. The effect of a quality improvement intervention on perceived sleep quality and cognition in a medical ICU. Crit Care Med. 2013;41(3):800-809. doi:10.1097/CCM.0b013e3182746442
Zhang Z, Pan L, Ni H. Impact of delirium on clinical outcome in critically ill patients: a meta-analysis. Gen Hosp Psychiatry. 2013;35(2):105-111. doi:10.1016/j.genhosppsych.2012.11.003
Duclos C, Dumont M, Blais H, et al. Rest-activity cycle disturbances in the acute phase of moderate to severe traumatic brain injury. Neurorehabil Neural Repair. 2014;28(5):472-482. doi:10.1177/1545968313517756
Kamdar BB, King LM, Collop NA, et al. The effect of a quality improvement intervention on perceived sleep quality and cognition in a medical ICU. Crit Care Med. 2013;41(3):800-809. doi:10.1097/CCM.0b013e3182746442
Weinhouse GL, Schwab RJ, Watson PL, et al. Bench-to-bedside review: delirium in ICU patients - importance of sleep deprivation. Crit Care. 2009;13(6):234. doi:10.1186/cc8131
Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004;291(14):1753-1762. doi:10.1001/jama.291.14.1753
Pandharipande PP, Girard TD, Jackson JC, et al. Long-term cognitive impairment after critical illness. N Engl J Med. 2013;369(14):1306-1316. doi:10.1056/NEJMoa1301372
Bryant PA, Trinder J, Curtis N. Sick and tired: Does sleep have a vital role in the immune system? Nat Rev Immunol. 2004;4(6):457-467. doi:10.1038/nri1369
Besedovsky L, Lange T, Born J. Sleep and immune function. Pflugers Arch. 2012;463(1):121-137. doi:10.1007/s00424-011-1044-0
Knauert MP, Haspel JA, Pisani MA. Sleep loss and circadian rhythm disruption in the intensive care unit. Clin Chest Med. 2015;36(3):419-429. doi:10.1016/j.ccm.2015.05.008
Mullington JM, Haack M, Toth M, et al. Cardiovascular, inflammatory, and metabolic consequences of sleep deprivation. Prog Cardiovasc Dis. 2009;51(4):294-302. doi:10.1016/j.pcad.2008.10.003
Irwin MR. Why sleep is important for health: a psychoneuroimmunology perspective. Annu Rev Psychol. 2015;66:143-172. doi:10.1146/annurev-psych-010213-115205
Tobin MJ, Laghi F, Jubran A. Why COVID-19 silent hypoxemia is baffling to physicians. Am J Respir Crit Care Med. 2020;202(3):356-360. doi:10.1164/rccm.202006-2157CP
Rittayamai N, Tscheikuna J, Rujiwit P. High-flow nasal cannula versus conventional oxygen therapy after endotracheal extubation: a randomized crossover physiologic study. Respir Care. 2014;59(4):485-490. doi:10.4187/respcare.02397
Chen HI, Tang YR. Sleep loss impairs inspiratory muscle endurance. Am Rev Respir Dis. 1989;140(4):907-909. doi:10.1164/ajrccm/140.4.907
Van Cauter E, Leproult R, Plat L. Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. JAMA. 2000;284(7):861-868. doi:10.1001/jama.284.7.861
Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet. 1999;354(9188):1435-1439. doi:10.1016/S0140-6736(99)01376-8
Friese RS, Diaz-Arrastia R, McBride D, et al. Quantity and quality of sleep in the surgical intensive care unit: are our patients sleeping? J Trauma. 2007;63(6):1210-1214. doi:10.1097/TA.0b013e31815b83d7
Fanfulla F, Ceriana P, D'Artavilla Lupo N, et al. Sleep disturbances in patients admitted to a step-down unit after ICU discharge: the role of mechanical ventilation. Sleep. 2011;34(3):355-362. doi:10.1093/sleep/34.3.355
Gehlbach BK, Chapotot F, Leproult R, et al. Temporal disorganization of circadian rhythmicity and sleep-wake regulation in mechanically ventilated patients receiving continuous intravenous sedation. Sleep. 2012;35(8):1105-1114. doi:10.5665/sleep.1998
Simons KS, Verweij E, Lemmens PMC, et al. Noise in the intensive care unit and its influence on sleep quality: a multicenter observational study in Dutch intensive care units. Crit Care. 2018;22(1):250. doi:10.1186/s13054-018-2182-y
Patel J, Baldwin J, Bunting P, et al. The effect of a multicomponent multidisciplinary bundle of interventions on sleep and delirium in medical and surgical intensive care patients. Anaesthesia. 2014;69(6):540-549. doi:10.1111/anae.12638
Konkani A, Oakley B. Noise in hospital intensive care units--a critical review of a critical topic. J Crit Care. 2012;27(5):522.e1-522.e9. doi:10.1016/j.jcrc.2011.09.003
Litton E, Carnegie V, Elliott R, et al. The efficacy of earplugs as a sleep hygiene strategy for reducing delirium in the ICU: a systematic review and meta-analysis. Crit Care Med. 2016;44(5):992-999. doi:10.1097/CCM.0000000000001557
Kahn DM, Cook TE, Carlisle CC, et al. Identification and modification of environmental noise in an ICU setting. Chest. 1998;114(2):535-540. doi:10.1378/chest.114.2.535
Engwall M, Fridh I, Johansson L, et al. Lighting, sleep and circadian rhythm: An intervention study in the intensive care unit. Intensive Crit Care Nurs. 2015;31(6):325-335. doi:10.1016/j.iccn.2015.07.001
Beauchemin KM, Hays P. Dying in the dark: sunshine, gender and outcomes in myocardial infarction. J R Soc Med. 1998;91(7):352-354. doi:10.1177/014107689809100703
Wunsch H, Gershengorn H, Mayer SA, et al. The effect of window rooms on critically ill patients with subarachnoid hemorrhage admitted to intensive care. Crit Care. 2011;15(2):R81. doi:10.1186/cc10075
Simons KS, Laheij RJF, van den Boogaard M, et al. Dynamic light application therapy to reduce the incidence and duration of delirium in intensive-care patients: a randomised controlled trial. Lancet Respir Med. 2016;4(3):194-202. doi:10.1016/S2213-2600(16)00025-4
Manzano F, Pérez-Pérez AM, Martínez-Ruiz S, et al. Hospital-acquired pressure ulcers and risk of hospital mortality in intensive care patients on mechanical ventilation. J Eval Clin Pract. 2014;20(4):362-368. doi:10.1111/jep.12137
Gelinas C, Fillion L, Puntillo KA, et al. Validation of the critical-care pain observation tool in adult patients. Am J Crit Care. 2006;15(4):420-427. doi:10.4037/ajcc2006.15.4.420
Mäkinen TM, Juvonen R, Jokelainen J, et al. Cold temperature and low humidity are associated with increased occurrence of respiratory tract infections. Respir Med. 2009;103(3):456-462. doi:10.1016/j.rmed.2008.09.011
Olson DM, Borel CO, Laskowitz DT, et al. Quiet time: a nursing intervention to promote sleep in neurocritical care units. Am J Crit Care. 2001;10(2):74-78. doi:10.4037/ajcc2001.10.2.74
Dennis CM, Lee R, Woodard EK, et al. Benefits of quiet time for neuro-intensive care patients. J Neurosci Nurs. 2010;42(4):217-224. doi:10.1097/JNN.0b013e3181e26c20
Eliassen KM, Hopstock LA. Sleep promotion in the intensive care unit—a survey of nurses' interventions. Intensive Crit Care Nurs. 2011;27(3):138-142. doi:10.1016/j.iccn.2011.03.001
Alexopoulou C, Kondili E, Plataki M, et al. Patient-ventilator synchrony and sleep quality with proportional assist and pressure support ventilation. Intensive Care Med. 2013;39(6):1040-1047. doi:10.1007/s00134-013-2850-y
Fanfulla F, Delmastro M, Berardinelli A, et al. Effects of different ventilator settings on sleep and inspiratory effort in patients with neuromuscular disease. Am J Respir Crit Care Med. 2005;172(5):619-624. doi:10.1164/rccm.200406-694OC
Richards KC, Gibson R, Overton-McCoy AL. Effects of massage in acute and critical care. AACN Clin Issues. 2000;11(1):77-96. doi:10.1097/00044067-200002000-00010
Su CP, Lai HL, Chang ET, et al. A randomized controlled trial of the effects of listening to non-commercial music on quality of nocturnal sleep and relaxation indices in patients in medical intensive care unit. J Adv Nurs. 2013;69(6):1377-1389. doi:10.1111/jan.12005
Hu RF, Jiang XY, Chen J, et al. Non-pharmacological interventions for sleep promotion in the intensive care unit. Cochrane Database Syst Rev. 2018;2018(10):CD008808. doi:10.1002/14651858.CD008808.pub3
Bourne RS, Mills GH, Minelli C. Melatonin therapy to improve nocturnal sleep in critically ill patients: encouraging results from a small randomised controlled trial. Crit Care. 2008;12(2):R52. doi:10.1186/cc6871
Ibrahim MG, Bellomo R, Hart GK, et al. A double-blind placebo-controlled randomised pilot study of nocturnal melatonin in tracheostomised patients. Crit Care Resusc. 2006;8(3):187-191.
Hatta K, Kishi Y, Wada K, et al. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry. 2014;71(4):397-403. doi:10.1001/jamapsychiatry.2013.3320
Baumgartner L, Lam K, Lai J, et al. Effectiveness of melatonin for the prevention of intensive care unit delirium. Pharmacotherapy. 2019;39(3):280-287. doi:10.1002/phar.2222
Mo Y, Scheer CE, Abdallah GT. Emerging role of melatonin and melatonin receptor agonists in sleep and delirium in intensive care unit patients. J Intensive Care Med. 2016;31(7):451-455. doi:10.1177/0885066615592348
Oto J, Yamamoto K, Koike S, et al. Sleep quality of mechanically ventilated patients sedated with dexmedetomidine. Intensive Care Med. 2012;38(12):1982-1989. doi:10.1007/s00134-012-2685-y
Zaal IJ, Devlin JW, Hazelbag M, et al. Benzodiazepine-associated delirium in critically ill adults. Intensive Care Med. 2015;41(12):2130-2137. doi:10.1007/s00134-015-4063-z
Nikooie R, Neufeld KJ, Oh ES, et al. Antipsychotics for treating delirium in hospitalized adults: a systematic review. Ann Intern Med. 2019;171(7):485-495. doi:10.7326/M19-1860
Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263-306. doi:10.1097/CCM.0b013e3182783b72
Flannery AH, Oyler DR, Weinhouse GL. The impact of interventions to improve sleep on delirium in the ICU: a systematic review and research framework. Crit Care Med. 2016;44(12):2231-2240. doi:10.1097/CCM.0000000000001952
Boyko Y, Jennum P, Toft P. Sleep quality and circadian rhythm disruption in the intensive care unit: a review. Nat Sci Sleep. 2017;9:277-284. doi:10.2147/NSS.S151525
Van Rompaey B, Elseviers MM, Van Drom W, et al. The effect of earplugs during the night on the onset of delirium and sleep perception: a randomized controlled trial in intensive care patients. Crit Care. 2012;16(3):R73. doi:10.1186/cc11330
Patel J, Baldwin J, Bunting P, et al. The effect of a multicomponent multidisciplinary bundle of interventions on sleep and delirium in medical and surgical intensive care patients. Anaesthesia. 2014;69(6):540-549. doi:10.1111/anae.12638
Kamdar BB, Kamdar BB, Needham DM. Bundling sleep promotion with delirium prevention: ready for prime time? Anaesthesia. 2014;69(6):527-531. doi:10.1111/anae.12686
Hshieh TT, Yue J, Oh E, et al. Effectiveness of multicomponent nonpharmacological delirium interventions: a meta-analysis. JAMA Intern Med. 2015;175(4):512-520. doi:10.1001/jamainternmed.2014.7779
Matthew D, Schallom L, Min A, et al. A quality improvement approach to implementing a sleep promotion protocol in a surgical intensive care unit. Crit Care Nurse. 2019;39(4):20-28. doi:10.4037/ccn2019692
Delaney LJ, Currie MJ, Huang HC, et al. Investigating the application of motion accelerometers as a sleep monitoring technique and the clinical burden of the intensive care environment on sleep quality: study protocol for a prospective observational study in Australia. BMJ Open. 2018;8(1):e019704. doi:10.1136/bmjopen-2017-019704
Kamdar BB, Yang J, King LM, et al. Developing, implementing, and evaluating a multifaceted quality improvement intervention to promote sleep in an ICU. Am J Med Qual. 2014;29(6):546-554. doi:10.1177/1062860613509684
Howell D, Oliver TK, Keller-Olaman S, et al. Sleep disturbance in adults with cancer: a systematic review of evidence for best practices in assessment and management for clinical practice. Ann Oncol. 2014;25(4):791-800. doi:10.1093/annonc/mdt506
Knauert MP, Redeker NS, Yaggi HK, et al. Creating naptime: an overnight, nonpharmacologic intensive care unit sleep promotion protocol. J Patient Exp. 2018;5(3):180-187. doi:10.1177/2374373517747242
Ding Q, Redeker NS, Pisani MA, et al. Factors influencing patients' sleep in the intensive care unit: perceptions of patients and clinical staff. Am J Crit Care. 2017;26(4):278-286. doi:10.4037/ajcc2017333
Elliott R, McKinley S. The development of a clinical practice guideline to improve sleep in intensive care patients: a solution focused approach. Intensive Crit Care Nurs. 2014;30(5):246-256. doi:10.1016/j.iccn.2014.04.003
Goetz MB, Hoang T, Knapp H, et al. Central implementation strategies outperform local ones in improving HIV testing in Veterans Healthcare Administration facilities. J Gen Intern Med. 2013;28(10):1311-1317. doi:10.1007/s11606-013-2420-6
Jaiswal SJ, McCarthy TJ, Wineinger NE, et al. Melatonin and sleep in preventing hospitalized delirium: a randomized clinical trial. Am J Med. 2018;131(9):1110-1117.e4. doi:10.1016/j.amjmed.2018.04.009
Kamdar BB, Martin JL, Needham DM. Noise and light pollution in the hospital: a call for action. J Hosp Med. 2017;12(10):861-862. doi:10.12788/jhm.2838
Milbrandt EB, Deppen S, Harrison PL, et al. Costs associated with delirium in mechanically ventilated patients. Crit Care Med. 2004;32(4):955-962. doi:10.1097/01.ccm.0000119429.16055.92
Matthews EE. Sleep disturbances and fatigue in critically ill patients. AACN Adv Crit Care. 2011;22(3):204-224. doi:10.1097/NCI.0b013e31822052cb
Mistraletti G, Carloni E, Cigada M, et al. Sleep and delirium in the intensive care unit. Minerva Anestesiol. 2008;74(6):329-333.
Mundigler G, Delle-Karth G, Koreny M, et al. Impaired circadian rhythm of melatonin secretion in sedated critically ill patients with severe sepsis. Crit Care Med. 2002;30(3):536-540. doi:10.1097/00003246-200203000-00007
Ono H, Taguchi T, Kido Y, et al. The usefulness of bright light therapy for patients after oesophagectomy. Intensive Crit Care Nurs. 2011;27(3):158-166. doi:10.1016/j.iccn.2011.03.003
Pandharipande P, Ely EW. Sedative and analgesic medications: risk factors for delirium and sleep disturbances in the critically ill. Crit Care Clin. 2006;22(2):313-327. doi:10.1016/j.ccc.2006.02.010
Patel J, Baldwin J, Bunting P, et al. The effect of a multicomponent multidisciplinary bundle of interventions on sleep and delirium in medical and surgical intensive care patients. Anaesthesia. 2014;69(6):540-549. doi:10.1111/anae.12638
Pulak LM, Jensen L. Sleep in the intensive care unit: a review. J Intensive Care Med. 2016;31(1):14-23. doi:10.1177/0885066614538749
Scotto CJ, McClusky C, Spillan S, et al. Earplugs improve patients' subjective experience of sleep in critical care. Nurs Crit Care. 2009;14(4):180-184. doi:10.1111/j.1478-5153.2009.00344.x
Tembo AC, Parker V, Higgins I. The experience of sleep deprivation in intensive care patients: findings from a larger hermeneutic phenomenological study. Intensive Crit Care Nurs. 2013;29(6):310-316. doi:10.1016/j.iccn.2013.05.003
Wang J, Greenberg H. Sleep and the ICU. Open Crit Care Med J. 2013;6(1):80-87. doi:10.2174/1874828701306010080

Acute Endocrinology in Critical Care

Acute Endocrinology in Critical Care: A Comprehensive Review for Residents

Dr Neeraj Manikath ,claude.ai

Abstract

Endocrine emergencies represent a significant proportion of critical illness presentations in intensive care units (ICUs) and require prompt recognition and management to prevent adverse outcomes. This review provides critical care residents with an evidence-based approach to the diagnosis and management of common acute endocrine disorders encountered in the ICU setting. We discuss diabetic emergencies, thyroid crises, adrenal insufficiency, pituitary disorders, and electrolyte abnormalities with a focus on practical management strategies informed by recent literature and clinical guidelines.

Introduction

Endocrine emergencies constitute a diverse group of conditions that can precipitate or complicate critical illness. The stress response to critical illness itself often leads to significant alterations in endocrine function, creating a complex interplay between primary endocrine disorders and adaptive or maladaptive responses to severe illness. Critical care physicians must be adept at recognizing these conditions, understanding their pathophysiology, and implementing timely interventions to optimize outcomes.

This review aims to provide a practical framework for the diagnosis and management of acute endocrine emergencies in the ICU setting, with a focus on the most commonly encountered conditions and recent evidence-based approaches to their management.

Diabetic Emergencies

Diabetic Ketoacidosis (DKA)

Diabetic ketoacidosis remains a common and potentially life-threatening complication of diabetes mellitus, particularly in type 1 diabetes. While mortality has decreased significantly over the past decades, it remains an important cause of morbidity and ICU admission.

Pathophysiology

DKA results from absolute or relative insulin deficiency coupled with increased counterregulatory hormones (glucagon, catecholamines, cortisol, and growth hormone), leading to hyperglycemia, ketogenesis, and metabolic acidosis. Critical illness can precipitate DKA through stress-induced counterregulatory hormone release and inflammatory cytokines that enhance insulin resistance.

Diagnosis

The diagnostic criteria for DKA include:

- Hyperglycemia (glucose >250 mg/dL, though "euglycemic DKA" can occur with lower glucose levels, particularly in patients on SGLT2 inhibitors)

- Metabolic acidosis (pH <7.3, bicarbonate <18 mEq/L)

- Ketonemia or ketonuria

Laboratory assessments should include:

- Complete blood count (CBC)

- Comprehensive metabolic panel

- Blood glucose

- Serum ketones (β-hydroxybutyrate is preferred over acetoacetate)

- Arterial blood gas

- Urinalysis

- Cultures and imaging as indicated to identify precipitating causes

Management

The cornerstone of DKA management follows these principles:

1. Fluid Resuscitation: Initial fluid deficit in DKA typically ranges from 5-10 L. Begin with isotonic crystalloids (0.9% saline) at 15-20 mL/kg/hr for the first hour, then adjust rates based on hemodynamic monitoring.

2. Insulin Therapy: After initial fluid resuscitation has begun, start an intravenous insulin infusion at 0.1 units/kg/hr. Continue until anion gap closure, then transition to subcutaneous insulin with an overlap period.

3. Electrolyte Replacement:

- Potassium: Replete when serum potassium <5.2 mEq/L to maintain levels between 4-5 mEq/L

- Phosphate: Consider replacement for severe hypophosphatemia (<1.0 mg/dL)

- Magnesium: Maintain normal levels

4. Bicarbonate Therapy: Generally not recommended except in severe acidosis (pH <6.9) or when accompanied by hemodynamic instability despite adequate fluid resuscitation.

5. Transition to Subcutaneous Insulin: When DKA has resolved (glucose <200 mg/dL, anion gap normalized, pH >7.3), transition to subcutaneous insulin with an overlap of 1-2 hours with IV insulin to prevent relapse.

Recent studies suggest that lower rates of insulin infusion (0.05-0.1 units/kg/hr) may be as effective as traditional higher doses while reducing the risk of hypoglycemia and hypokalemia. Furthermore, rapid acting insulin analogues administered subcutaneously every 1-2 hours have shown similar efficacy to IV insulin in mild to moderate DKA, although IV insulin remains the standard for severe cases or patients with hemodynamic instability.

Hyperosmolar Hyperglycemic State (HHS)

HHS typically affects elderly patients with type 2 diabetes and is characterized by severe hyperglycemia, hyperosmolality, and severe dehydration without significant ketoacidosis.

Diagnosis

Diagnostic criteria include:

- Plasma glucose >600 mg/dL

- Serum osmolality >320 mOsm/kg

- Absence of significant ketosis/ketoacidosis

- Profound dehydration

Management

Management principles are similar to DKA but with several important distinctions:

1. Fluid Resuscitation: More aggressive fluid replacement is often required due to more severe dehydration. Initial crystalloid selection should be guided by serum sodium (corrected for hyperglycemia).

2. Insulin Therapy: Lower insulin doses are typically needed compared to DKA. Starting at 0.05-0.1 units/kg/hr is appropriate, with a focus on gradual glucose reduction (50-75 mg/dL/hr) to avoid rapid osmolar shifts and cerebral edema.

3. Thromboprophylaxis: HHS carries a high risk of thrombotic complications; early initiation of prophylactic anticoagulation is recommended unless contraindicated.

Hypoglycemia in the ICU

Iatrogenic hypoglycemia remains a significant concern in critically ill patients, particularly during intensive insulin therapy. Hypoglycemia is independently associated with increased mortality in ICU patients.

Management

Treatment principles include:

- IV dextrose 50% (25g) for severe hypoglycemia

- Continuous glucose infusion may be required for prolonged hypoglycemia, particularly with long-acting insulin or sulfonylurea overdose

- Octreotide may be useful in sulfonylurea-induced hypoglycemia

Current guidelines recommend targeting blood glucose levels between 140-180 mg/dL in most critically ill patients, as this range balances the risks of hyperglycemia with those of hypoglycemia.

Thyroid Emergencies

Thyroid Storm

Thyroid storm represents the extreme manifestation of thyrotoxicosis and is associated with significant mortality (10-30%) even with optimal treatment.

Diagnosis

Clinical diagnosis is based on the presence of severe thyrotoxicosis with evidence of systemic decompensation:

- Hyperthermia

- Tachycardia out of proportion to fever

- Central nervous system effects (agitation, delirium, psychosis, coma)

- Gastrointestinal dysfunction (nausea, vomiting, diarrhea)

- Cardiovascular dysfunction (heart failure, hypotension)

The Burch-Wartofsky Point Scale can help assess the probability of thyroid storm.

Management

Treatment must be initiated based on clinical suspicion without waiting for laboratory confirmation:

1. Anti-thyroid drugs: Thionamides block new hormone synthesis.

- Propylthiouracil (PTU): 600-1000 mg loading dose, then 200-250 mg every 4 hours

- Methimazole: 60-80 mg loading dose, then 20-30 mg every 6 hours

- PTU is preferred initially due to additional inhibition of peripheral T4 to T3 conversion

2. Iodine solutions: Inhibit thyroid hormone release (Wolff-Chaikoff effect)

- Start 1 hour after thionamides to prevent iodine utilization for increased hormone synthesis

- Lugol's solution (8 drops q6h) or potassium iodide (5 drops q6h)

3. Beta-blockers: Control adrenergic symptoms

- Propranolol 60-80 mg orally every 4-6 hours or 1-2 mg IV q4h

- Esmolol infusion is an alternative for better titration in hemodynamically unstable patients

4. Glucocorticoids: Inhibit peripheral conversion of T4 to T3 and treat potential relative adrenal insufficiency

- Hydrocortisone 100 mg IV q8h or dexamethasone 2-4 mg IV q6h

5. Supportive care:

- Aggressive cooling for hyperthermia

- Fluid resuscitation

- Nutritional support

- Treatment of precipitating cause

Plasma exchange or plasmapheresis may be considered in refractory cases unresponsive to conventional therapy.

Myxedema Coma

Myxedema coma is a rare but life-threatening manifestation of severe hypothyroidism with mortality rates of 20-50%.

Diagnosis

Clinical features include:

- Altered mental status

- Hypothermia

- Bradycardia

- Hypoventilation

- Non-pitting edema

- Delayed relaxation of deep tendon reflexes

Laboratory findings typically show:

- Elevated TSH (except in secondary hypothyroidism)

- Low free T4 and T3

- Hyponatremia

- Hypoglycemia

- Hypercapnia

Management

1. Thyroid hormone replacement:

- Levothyroxine (T4): 300-500 μg IV loading dose, followed by 50-100 μg IV daily

- Consider adding liothyronine (T3) in patients with cardiovascular compromise: 5-20 μg IV q8h

2. Glucocorticoids:

- Hydrocortisone 100 mg IV q8h until coexisting adrenal insufficiency is ruled out

3. Supportive care:

- Passive rewarming (aggressive rewarming can cause vasodilation and cardiovascular collapse)

- Cautious fluid resuscitation

- Correction of electrolyte abnormalities

- Ventilatory support as needed

- Treatment of precipitating factors

Adrenal Emergencies

Adrenal Crisis

Adrenal crisis is a life-threatening emergency characterized by circulatory collapse and electrolyte abnormalities resulting from glucocorticoid deficiency.

Diagnosis

Clinical features include:

- Hypotension refractory to fluids

- Abdominal pain, nausea, vomiting

- Fever

- Altered mental status

- Hyperpigmentation (in primary adrenal insufficiency)

Laboratory findings:

- Hyponatremia

- Hyperkalemia (primarily in primary adrenal insufficiency)

- Hypoglycemia

- Eosinophilia

- Elevated BUN/creatinine

Diagnosis is confirmed with random cortisol and ACTH levels, followed by ACTH stimulation test once the patient is stabilized. However, treatment should not be delayed pending test results.

Management

1. Glucocorticoid replacement:

- Hydrocortisone 100 mg IV bolus, followed by 50-100 mg IV q6-8h or continuous infusion of 200-300 mg/24h

- Transition to oral replacement when patient is stable

2. Fluid resuscitation:

- Normal saline 1-2 L in the first hour, followed by continuous infusion guided by hemodynamic parameters

3. Vasopressors:

- May be required despite adequate fluid and steroid replacement

- Norepinephrine is generally preferred

4. Electrolyte management:

- Correct hypoglycemia with dextrose

- Monitor and correct electrolyte abnormalities

5. Mineralocorticoid replacement:

- Generally not needed during acute crisis management (high-dose hydrocortisone provides sufficient mineralocorticoid effect)

- Add fludrocortisone 0.1 mg daily once hydrocortisone doses are below 50 mg/day in primary adrenal insufficiency

Critical Illness-Related Corticosteroid Insufficiency (CIRCI)

CIRCI refers to inadequate corticosteroid activity relative to the severity of a patient's illness, resulting from dysfunction at any level of the hypothalamic-pituitary-adrenal (HPA) axis.

Diagnosis

The diagnosis remains challenging due to:

- Variable cortisol cutoffs in different studies

- Effects of hypoalbuminemia on total cortisol measurements

- Variable cortisol response in different critical illnesses

The 2017 guidelines of the Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) suggest:

- Delta cortisol <9 μg/dL after cosyntropin 250 μg AND

- Random total cortisol <10 μg/dL

However, these criteria remain controversial, and clinical judgment is essential.

Management

The use of corticosteroids in CIRCI remains controversial and should be guided by specific clinical scenarios:

1. Septic shock:

- Consider hydrocortisone 200-300 mg/day in divided doses or continuous infusion for patients with refractory shock despite adequate fluid resuscitation and vasopressor support

- Continue for 7 days or until vasopressors are discontinued

2. ARDS:

- Consider methylprednisolone in moderate to severe ARDS

- Initial dose 1 mg/kg/day, followed by gradual taper

3. Post-cardiac surgery vasoplegic shock:

- Hydrocortisone may reduce vasopressor requirements and ICU length of stay

The ADRENAL trial (2018) showed no mortality benefit but faster shock resolution with hydrocortisone in septic shock, while the APROCCHSS trial (2018) demonstrated reduced mortality with the combination of hydrocortisone and fludrocortisone.

Pituitary Emergencies

Pituitary Apoplexy

Pituitary apoplexy is a medical emergency resulting from sudden hemorrhage or infarction of the pituitary gland, often within a pre-existing adenoma.

Diagnosis

Clinical features include:

- Sudden onset of severe headache

- Visual disturbances (visual field defects, reduced acuity, ophthalmoplegia)

- Altered mental status

- Signs of meningeal irritation

- Features of hypopituitarism

Diagnosis is confirmed with urgent MRI showing hemorrhage or infarction in the pituitary gland.

Management

1. Hormonal replacement:

- Hydrocortisone 100 mg IV q6-8h (priority - adrenal crisis can be life-threatening)

- Thyroid hormone replacement if secondary hypothyroidism is present

2. Neurosurgical evaluation:

- Urgent decompression may be needed for severe visual impairment or declining consciousness

3. Supportive care:

- Fluid and electrolyte management

- Correction of other hormonal deficiencies once stabilized

Syndrome of Inappropriate ADH Secretion (SIADH)

SIADH is a common cause of hyponatremia in critically ill patients and is characterized by inappropriate release of vasopressin leading to water retention.

Diagnosis

Diagnostic criteria include:

- Hypotonic hyponatremia (serum Na⁺ <135 mEq/L)

- Decreased serum osmolality (<275 mOsm/kg)

- Inappropriate urine concentration (urine osmolality >100 mOsm/kg)

- Elevated urine sodium (>30 mEq/L with normal salt intake)

- Normal adrenal, thyroid, and kidney function

- Absence of diuretic use or significant hypovolemia

Management

1. Mild asymptomatic hyponatremia (Na⁺ >125 mEq/L):

- Fluid restriction (800-1000 mL/day)

2. Moderate symptomatic hyponatremia (Na⁺ 120-125 mEq/L):

- Fluid restriction

- Consider vasopressin receptor antagonists (vaptans) in chronic cases

3. Severe symptomatic hyponatremia (Na⁺ <120 mEq/L) or neurological symptoms:

- Hypertonic saline (3%) 100-150 mL over 10-20 minutes, may repeat 2-3 times

- Target correction rate: 4-6 mEq/L in first 24 hours to avoid osmotic demyelination syndrome

- Consider continuous infusion with frequent electrolyte monitoring

4. Treat underlying cause when identified

Electrolyte Disorders in Endocrine Emergencies

Hypercalcemia

Severe hypercalcemia (Ca²⁺ >14 mg/dL) represents a medical emergency requiring ICU admission. Common causes in the ICU include malignancy, primary hyperparathyroidism, and medication effects.

Management

1. Aggressive hydration:

- Normal saline 200-300 mL/hr initially, then adjusted based on volume status

- Enhances calciuresis

2. Loop diuretics:

- Once adequately hydrated, furosemide 20-40 mg IV q2-4h

- Increases renal calcium excretion

3. Bisphosphonates:

- Zoledronic acid 4 mg IV over 15-30 minutes

- Onset of action within 24-48 hours

4. Calcitonin:

- 4 IU/kg SC/IM q12h

- Rapid but temporary effect (48-72 hours)

- Useful as bridge therapy

5. Glucocorticoids:

- Effective primarily in vitamin D-mediated or granulomatous causes

- Hydrocortisone 200-300 mg/day or equivalent

6. Dialysis:

- Consider in refractory cases or renal failure

Hyponatremia

Hyponatremia is the most common electrolyte disorder in hospitalized patients and is associated with increased mortality.

Management

Management depends on the etiology, severity, and chronicity:

1. Severe symptomatic hyponatremia (Na⁺ <120 mEq/L with neurological symptoms):

- Hypertonic saline (3%) boluses: 100 mL over 10 minutes, repeat up to 3 times as needed

- Target increase: 4-6 mEq/L in first 24 hours

- Maximum correction rate: 8-10 mEq/L in 24 hours and 18 mEq/L in 48 hours

- Frequent monitoring (every 2-4 hours)

2. Chronic hyponatremia (>48 hours):

- More conservative correction to avoid osmotic demyelination syndrome

- Target increase: <8 mEq/L in 24 hours

3. Hypervolemic hyponatremia:

- Fluid restriction

- Diuretics

- Treatment of underlying cause (heart failure, cirrhosis)

- Consider vaptans in appropriate patients

4. Hypovolemic hyponatremia:

- Isotonic saline to restore volume status

- Treatment of underlying cause

Glucose Control in the ICU

Glycemic management remains a cornerstone of critical care. Following the publication of the NICE-SUGAR trial, which demonstrated increased mortality with intensive glucose control (81-108 mg/dL) compared to conventional control (<180 mg/dL), most guidelines now recommend targeting blood glucose levels between 140-180 mg/dL in critically ill patients.

Insulin Protocols

- Computer-guided or nurse-driven protocols based on frequent monitoring improve glycemic control

- Subcutaneous insulin regimens are appropriate for stable patients tolerating enteral nutrition

- Continuous insulin infusions are preferred for:

- Diabetic emergencies

- NPO status or variable nutritional intake

- Hemodynamic instability

- Liver failure

- Significant insulin resistance

Special Considerations

1. Enteral nutrition interruptions:

- Reduce insulin doses by 50-80% when feeds are interrupted

- Consider dextrose infusion during prolonged interruptions

2. Steroid therapy:

- Significant hyperglycemia may develop even in non-diabetic patients

- Insulin requirements often increase dramatically

- Consider separate "steroid-specific" insulin dosing

3. Continuous Renal Replacement Therapy (CRRT):

- May reduce insulin requirements due to clearance of counterregulatory hormones

- Dextrose-containing replacement fluids may increase glucose levels

Conclusion

Endocrine emergencies in critical care require prompt recognition and management to optimize outcomes. A systematic approach to diagnosis and treatment, coupled with awareness of recent evidence and guidelines, allows critical care physicians to effectively manage these complex conditions. Future research focusing on individualized approaches to hormone replacement and targeted therapies holds promise for further improving outcomes in critically ill patients with endocrine disorders.

References

1. American Diabetes Association. Standards of Medical Care in Diabetes—2025. *Diabetes Care* 2025;48(Supplement 1):S1-S278.

2. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. *Diabetes Care* 2009;32(7):1335-1343.

3. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. *Thyroid* 2016;26(10):1343-1421.

4. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the Treatment of Hypothyroidism. *Thyroid* 2014;24(12):1670-1751.

5. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 2016;101(2):364-389.

6. Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. *Crit Care Med* 2017;45(12):2078-2088.

7. Venkatesh B, Finfer S, Cohen J, et al. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. *N Engl J Med* 2018;378(9):797-808.

8. Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. *N Engl J Med* 2018;378(9):809-818.

9. NICE-SUGAR Study Investigators. Intensive versus Conventional Glucose Control in Critically Ill Patients. *N Engl J Med* 2009;360(13):1283-1297.

10. Rajendran R, Rayman G. Critical illness-induced dysglycaemia: diabetes and beyond. *Critical Care* 2014;18(6):701.

11. Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. *Nephrol Dial Transplant* 2014;29(suppl 2):i1-i39.

12. Carroll R, Matfin G. Endocrine and metabolic emergencies: thyroid storm. *Ther Adv Endocrinol Metab* 2010;1(3):139-145.

13. Chew MS, Itenov TS, Johansen ME, et al. Hypothalamic-pituitary-adrenal axis in sepsis: a retrospective cohort study. *Crit Care* 2019;23(1):336.

14. Rajasekaran S, Vanderpump M, Baldeweg S, et al. UK guidelines for the management of pituitary apoplexy. *Clin Endocrinol (Oxf)* 2011;74(1):9-20.

15. Boonen E, Van den Berghe G. Endocrine responses to critical illness: novel insights and therapeutic implications. *J Clin Endocrinol Metab* 2014;99(5):1569-1582.

16. Plummer MP, Bellomo R, Cousins CE, et al. Dysglycaemia in the critically ill and the interaction of chronic and acute glycaemia with mortality. *Intensive Care Med* 2014;40(7):973-980.

17. Gosmanov AR, Gosmanova EO, Dillard-Cannon E. Management of adult diabetic ketoacidosis. *Diabetes Metab Syndr Obes* 2014;7:255-264.

18. Dhatariya KK, Vellanki P. Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA). *Curr Diab Rep* 2017;17(5):33.

19. Vellanki P, Umpierrez GE. Increasing Hospitalizations for DKA: A Need for Prevention Programs. *Diabetes Care* 2018;41(9):1839-1841.

20. Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis. *Endocr Pract* 2016;22(6):753-762.

21. Yamamoto T, Fukuda I, Shibayama S, et al. Myxedema coma with high-output heart failure caused by rhabdomyolysis. *Am J Emerg Med* 2018;36(7):1324.e5-1324.e7.

22. Chiha M, Samarasinghe S, Kabaker AS. Thyroid storm: an updated review. *J Intensive Care Med* 2015;30(3):131-140.

23. Satoh T, Isozaki O, Suzuki A, et al. 2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society. *Endocr J* 2016;63(12):1025-1064.

24. Bornstein SR. Predisposing factors for adrenal insufficiency. *N Engl J Med* 2009;360(22):2328-2339.

25. Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. *Crit Care Med* 2008;36(6):1937-1949.

26. Kavanagh BP, McCowen KC. Clinical practice. Glycemic control in the ICU. *N Engl J Med* 2010;363(26):2540-2546.

27. Marik PE, Bellomo R. Stress hyperglycemia: an essential survival response! *Crit Care Med* 2013;41(6):e93-e94.

28. Bagshaw SM, Bellomo R, Kellum JA. Oliguria, volume overload, and loop diuretics. *Crit Care Med* 2008;36(4 Suppl):S172-S178.

29. Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. *Am J Med* 2013;126(10 Suppl 1):S1-S42.

30. Greet V, Casaer MP, Mesotten D, et al. Severe hypoglycemia in critically ill patients: risk factors and outcomes. *Crit Care Med* 2020;48(4):e326-e334.

31. Fayfman M, Pasquel FJ, Umpierrez GE. Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. *Med Clin North Am* 2017;101(3):587-606.

32. Akirov A, Matveev V, Pinchevsky L, et al. Thyroid Hormone Replacement Therapy in Patients with Various Types of Hypothyroidism: A Systematic Review. *J Clin Med* 2021;10(17):3987.

33. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. *Lancet* 2017;390(10101):1550-1562.

34. De Jonghe B, Lacherade JC, Sharshar T, Outin H. Intensive care unit-acquired weakness: risk factors and prevention. *Crit Care Med* 2009;37(10 Suppl):S309-S315.

35. Patwari PP, Carroll MS, Rand CM, et al. A defect in the arousal response to hypoxia in neurofibromatosis type 1. *Am J Respir Crit Care Med* 2010;182(12):1445-1457.

36. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. *Endocrinol Metab Clin North Am* 1993;22(2):263-277.

37. Danziger J, Zeidel ML. Osmotic homeostasis. *Clin J Am Soc Nephrol* 2015;10(5):852-862.

38. Umpierrez GE, Klonoff DC. Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital. *Diabetes Care* 2018;41(8):1579-1589.

39. Lam SM, Coates PT. Hemofiltration for hypercalcemia. *Kidney Int* 2003;64(1):367.

40. Zaloga GP. Hypocalcemia in critically ill patients. *Crit Care Med* 1992;20(2):251-262.

41. Dutt TS, Sadasivam B, Jenitha B, et al. A comparative assessment of adrenal function and cortisol levels in critically ill patients. *Indian J Crit Care Med* 2015;19(6):326-332.

42. Salluh JI, Shinotsuka CR, Soares M, et al. Cortisol levels and adrenal response in severe community-acquired pneumonia: a systematic review of the literature. *J Crit Care* 2010;25(3):541.e1-8.

43. Wajngot A, Giacca A, Grill V, Vranic M, Efendic S. The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. *Proc Natl Acad Sci U S A* 1992;89(13):6035-6039.

44. Garber JR, Cobin RH, Gharib H, et al. American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults. *Endocr Pract* 2012;18(6):988-1028.

45. Marik PE, Zaloga GP. Adrenal insufficiency in the critically ill: a new look at an old problem. *Chest* 2002;122(5):1784-1796.

Fungemia in Critically Ill Patients

Fungemia in Critically Ill Patients: Diagnosis, Management, and Treatment Strategies

dr Neeraj Manikath ,claude.ai

Introduction

Fungemia, defined as the presence of fungi in the bloodstream, represents a significant challenge in critical care settings. The incidence of invasive fungal infections (IFIs) has risen dramatically over recent decades, particularly in intensive care units (ICUs) where critically ill patients with compromised immune systems, multiple comorbidities, and exposure to broad-spectrum antibiotics create perfect conditions for fungal opportunistic infections. Candida species account for approximately 70-90% of all fungemia cases, though other pathogens including Aspergillus, Cryptococcus, and emerging pathogens like Fusarium are increasingly documented. This review focuses on current approaches to suspecting, diagnosing, and treating fungemia in ICU and critically ill patients, with emphasis on evidence-based strategies for improving outcomes.

Epidemiology and Risk Factors

The incidence of fungemia varies by geographic region, patient population, and hospital setting, but ranges from 2-11 cases per 1,000 ICU admissions. Candida albicans remains the most commonly isolated species globally, though non-albicans Candida species (particularly C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei) now account for more than 50% of isolates in many centers, with important implications for antifungal resistance patterns.

Key Risk Factors

Several well-established risk factors should alert clinicians to the possibility of fungemia:

Prolonged ICU stay (>7 days)
Broad-spectrum antibiotic therapy (particularly prolonged courses)
Central venous catheters and other indwelling devices
Total parenteral nutrition
Recent abdominal surgery, particularly with anastomotic leakage
Immunosuppression (hematologic malignancies, solid organ/stem cell transplant, corticosteroids, biologic agents)
Renal replacement therapy
Mechanical ventilation (>48 hours)
Severe acute pancreatitis
Colonization with Candida at multiple sites

The presence of multiple risk factors dramatically increases the likelihood of fungemia, with colonization at two or more sites conferring particularly high risk.

Clinical Presentation and Suspecting Fungemia

The clinical presentation of fungemia is often nonspecific, making early suspicion challenging. Classic signs include:

Persistent or recurrent fever despite broad-spectrum antibiotics
Unexplained deterioration in clinical condition
New-onset septic shock refractory to appropriate antibacterial therapy
Persistent leukocytosis or leukopenia
Unexplained thrombocytopenia (common in candidiasis)
Endophthalmitis (more common in candidemia than bacterial bloodstream infections)
New-onset renal dysfunction

A high index of suspicion is critical in at-risk patients, as early appropriate therapy significantly improves outcomes. Fungemia should be considered in any critically ill patient with risk factors who demonstrates persistent fever or signs of infection despite appropriate antibacterial therapy.

Diagnostic Approaches

Conventional Methods

Blood cultures remain the gold standard for diagnosing fungemia but suffer from low sensitivity (approximately 50-70% for Candida species) and slow turnaround time (median time to positivity: 2-3 days).
Fungal isolation from sterile sites (CSF, pleural fluid, peritoneal fluid, tissue biopsy) adds diagnostic value.

Risk Prediction Scores

Several scoring systems have been developed to identify patients at high risk for invasive candidiasis:

Candida Colonization Index (CCI): Ratio of sites colonized with Candida to total sites cultured; CCI ≥0.5 is associated with increased risk.
Candida Score: Awards points for total parenteral nutrition (1 point), surgery (1 point), multifocal Candida colonization (1 point), and severe sepsis (2 points). A score ≥3 has shown good predictive value.
Ostrosky-Zeichner Rule: Combines multiple risk factors including antibiotics, central venous catheters, total parenteral nutrition, dialysis, major surgery, pancreatitis, corticosteroids, and immunosuppressants.

Biomarkers and Molecular Diagnostics

Recent advances have improved diagnostic capabilities:

1,3-β-D-glucan (BDG): A cell wall component of many fungi (except Cryptococcus and Mucorales). Meta-analyses suggest sensitivity of 75-80% and specificity of 80-85% for invasive fungal infections. Sequential measurements may enhance value.
Mannan antigen/anti-mannan antibodies: Specific for Candida infections, with improved performance when used in combination.
PCR-based assays: Offer improved sensitivity (>90%) with rapid results, though standardization remains challenging. Multiplex PCR panels can simultaneously detect common Candida species and resistance markers.
T2 Magnetic Resonance: FDA-approved rapid diagnostic providing species-level identification of common Candida species within hours, with sensitivity superior to blood cultures.
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS): Rapidly identifies fungal species from positive cultures, significantly reducing time to identification.

Management Strategies

Empiric Therapy

Empiric antifungal therapy should be considered in high-risk patients with suspected fungemia. The decision to initiate empiric therapy should balance the risks of delayed appropriate treatment against antifungal overuse. Consider empiric therapy when:

Multiple risk factors are present
Patient has persistent/recurrent fever or signs of infection despite appropriate antibacterial therapy
Positive biomarkers (e.g., elevated BDG)
High Candida score (≥3) or other risk prediction score

Preemptive Therapy

Preemptive therapy refers to treatment initiated based on non-culture microbiological evidence (e.g., positive PCR or BDG) before definitive culture results. This approach has shown promise in balancing early intervention with antimicrobial stewardship.

Targeted Therapy

Once a fungal pathogen is identified, therapy should be tailored based on:

Species identification
Antifungal susceptibility testing
Patient-specific factors (organ dysfunction, drug interactions)
Site of infection and complications (endocarditis, endophthalmitis, etc.)

Source Control

Source control measures are essential and include:

Prompt removal or exchange of central venous catheters (particularly for Candida parapsilosis)
Drainage of abscesses
Debridement of infected necrotic tissue
Removal of infected prosthetic devices when possible

Antifungal Agents

Echinocandins (First-line for most critically ill patients)

Caspofungin: Loading dose 70mg, then 50mg daily
Micafungin: 100-150mg daily
Anidulafungin: Loading dose 200mg, then 100mg daily

Echinocandins demonstrate excellent activity against most Candida species, favorable safety profiles, limited drug interactions, and are recommended as first-line agents for critically ill patients with suspected or proven candidiasis.

Azoles

Fluconazole: Loading dose 800mg, then 400-800mg daily
Voriconazole: Loading dose 6mg/kg q12h x2 doses, then 3-4mg/kg q12h
Posaconazole: 300mg daily (delayed-release tablets)
Isavuconazole: Loading dose 200mg q8h x6 doses, then 200mg daily

Consider azoles for step-down therapy after clinical stabilization and when susceptibility is confirmed. Fluconazole remains appropriate empiric therapy in hemodynamically stable patients without prior azole exposure or colonization with fluconazole-resistant species.

Polyenes

Amphotericin B deoxycholate: 0.7-1.0 mg/kg daily
Liposomal amphotericin B: 3-5 mg/kg daily

Reserved for refractory cases, suspected resistant pathogens, or when other agents are contraindicated. Liposomal formulations offer improved safety profiles but at higher cost.

Other Considerations

Flucytosine: Used primarily in combination with amphotericin B for cryptococcal infections or severe invasive candidiasis. Requires therapeutic drug monitoring.
Therapeutic drug monitoring (TDM) is recommended for voriconazole, posaconazole, and flucytosine due to variable pharmacokinetics and narrow therapeutic windows.

Duration of Therapy

For uncomplicated candidemia:

Continue treatment for 14 days after the first negative blood culture AND resolution of clinical signs of infection
Daily blood cultures until clearance is documented

For complicated infections (endocarditis, osteomyelitis, endophthalmitis, deep tissue infections):

Treatment duration typically 4-6 weeks or longer
Ophthalmologic examination recommended for all patients with candidemia
Imaging to rule out metastatic foci in patients with persistent fungemia

Prevention Strategies

Antifungal prophylaxis: May be considered in selected high-risk populations (e.g., liver transplant, certain hematological malignancies, recurrent gastrointestinal perforations)
Infection control measures:
- Hand hygiene
- Catheter care bundles
- Antibiotic stewardship programs
- Minimizing device days
Risk factor modification where possible:
- Early enteral nutrition over parenteral when feasible
- Glycemic control
- Judicious steroid use
- Prompt removal of unnecessary invasive devices

Emerging Therapeutic Approaches

Combination antifungal therapy: Limited evidence supports routine combination therapy, though it may be considered for severe infections with resistant organisms or refractory disease.
Immunomodulatory approaches: Adjunctive therapies targeting host immune response, including recombinant cytokines and granulocyte transfusions, remain investigational.
Novel antifungals: Several new agents with promising activity including fosmanogepix, ibrexafungerp, and olorofim are in late-stage development.

Conclusion

Fungemia in critically ill patients represents a significant diagnostic and therapeutic challenge. Successful management requires:

High clinical suspicion in at-risk patients
Rapid deployment of appropriate diagnostics
Early initiation of appropriate antifungal therapy
Aggressive source control
Appropriate treatment duration with monitoring for complications

A multidisciplinary approach involving critical care, infectious diseases, and clinical pharmacy is optimal. Future advances in rapid diagnostics and therapeutic options promise to further improve outcomes in this challenging patient population.

References

Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50.
Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med. 2015;373(15):1445-1456.
Bassetti M, Garnacho-Montero J, Calandra T, et al. Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Intensive Care Med. 2017;43(9):1225-1238.
Martin-Loeches I, Antonelli M, Cuenca-Estrella M, et al. ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med. 2019;45(6):789-805.
Clancy CJ, Nguyen MH. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56(9):1284-1292.
León C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34(3):730-737.
Timsit JF, Azoulay E, Schwebel C, et al. Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial. JAMA. 2016;316(15):1555-1564.
Cortegiani A, Misseri G, Fasciana T, Giammanco A, Giarratano A, Chowdhary A. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care. 2018;6:69.
Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother. 2018;73(suppl_1):i4-i13.
Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18 Suppl 7:19-37.
Bartoletti M, Pascale R, Cricca M, et al. Epidemiology of invasive fungal infection during sepsis: a multicenter prospective cohort study. Intensive Care Med. 2022;48(7):897-908.
Arendrup MC, Perlin DS. Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis. 2014;27(6):484-492.
Ostrosky-Zeichner L, Shoham S, Vazquez J, et al. MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis. 2014;58(9):1219-1226.
Koehler P, Hamprecht A, Bader O, et al. Epidemiology of invasive candidiasis and candidaemia in Germany: a five-year prospective nationwide surveillance study. J Antimicrob Chemother. 2021;76(7):1890-1899.
Clancy CJ, Pappas PG, Vazquez J, et al. Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. Clin Infect Dis. 2018;66(11):1678-1686.

Refractory Hypothyroidism

Refractory Hypothyroidism: Challenges in Diagnosis and Management

Dr Neeraj Manikath ,claude.ai

Abstract

Hypothyroidism is a common endocrine disorder affecting 4-10% of the global population. While most patients respond adequately to levothyroxine (LT4) therapy, approximately 10-15% experience persistent symptoms and abnormal thyroid function tests despite seemingly appropriate treatment, a condition termed refractory hypothyroidism. This review explores the definition, etiology, pathophysiology, diagnosis, and management strategies for refractory hypothyroidism, with emphasis on recent advances in understanding and treatment approaches. We highlight the importance of differentiating between true refractory cases and those with poor adherence or absorption issues, along with emerging therapeutic options for patients genuinely resistant to standard therapy.

Introduction

Hypothyroidism results from insufficient production of thyroid hormones, leading to a hypometabolic state characterized by fatigue, cold intolerance, weight gain, constipation, and cognitive impairment. The standard of care involves thyroid hormone replacement, predominantly with levothyroxine (LT4), a synthetic form of thyroxine (T4). While this therapy normalizes thyroid function tests and alleviates symptoms in most patients, a significant subset experiences persistent symptoms and/or abnormal laboratory values despite seemingly adequate replacement, presenting a challenging clinical scenario termed refractory hypothyroidism.

This review aims to provide a comprehensive overview of refractory hypothyroidism, examining its definition, prevalence, underlying mechanisms, diagnostic approaches, and management strategies, with particular attention to recent developments in the field and emerging therapeutic options.

Definition and Prevalence

Refractory hypothyroidism refers to the persistence of clinical manifestations of hypothyroidism and/or abnormal thyroid function tests despite seemingly appropriate thyroid hormone replacement therapy. The prevalence of this condition is estimated at 10-15% of treated hypothyroid patients, though exact figures vary depending on the criteria used for definition.

The condition can be subdivided into two categories:

Biochemical persistence: Patients with persistently elevated thyroid-stimulating hormone (TSH) despite standard or high-dose LT4 therapy
Symptomatic persistence: Patients with normalized TSH but persistent hypothyroid symptoms

Etiology and Pathophysiology

Medication Adherence Issues

Non-adherence to prescribed therapy is one of the most common causes of apparent treatment failure, estimated to account for 40-60% of cases of persistent hypothyroidism. Studies indicate that up to 40% of patients do not take levothyroxine as prescribed, highlighting the importance of addressing adherence before diagnosing true refractory disease.

Absorption Disorders

Gastrointestinal disorders affecting absorption represent another significant contributor to refractory hypothyroidism:

Celiac disease: Present in 2-5% of patients with refractory hypothyroidism
Helicobacter pylori infection: Reduces gastric acidity needed for LT4 absorption
Atrophic gastritis: Impairs acidic environment required for tablet dissolution
Small intestinal bacterial overgrowth (SIBO): Interferes with hormone absorption
Inflammatory bowel disease: Disrupts intestinal absorptive capacity
Post-surgical alterations: Gastric bypass, jejunostomy, or extensive small bowel resection

Drug Interactions

Several medications can interfere with LT4 absorption or metabolism:

Absorption inhibitors:
- Calcium and iron supplements
- Aluminum-containing antacids
- Proton pump inhibitors
- Sucralfate
- Bile acid sequestrants (cholestyramine)
- Phosphate binders
Metabolism enhancers:
- Carbamazepine
- Phenytoin
- Rifampin
- Phenobarbital
- Estrogens

Genetic Factors

Recent research has identified genetic variants affecting thyroid hormone action:

Thyroid hormone transporter defects: MCT8, MCT10, OATP mutations
Deiodinase enzyme variants: Affecting conversion of T4 to T3
Thyroid hormone receptor mutations: Causing reduced sensitivity to thyroid hormone

Increased Thyroid Hormone Requirement States

Certain physiological and pathological conditions increase thyroid hormone requirements:

Pregnancy: 30-50% increase in requirement
Aging: Altered metabolism and tissue sensitivity
Obesity: Reduced bioavailability due to increased distribution volume
Critical illness: Altered thyroid hormone metabolism

Diagnosis and Evaluation

Clinical Assessment

A comprehensive evaluation includes:

Detailed medication history, including timing of LT4 relative to food and other medications
Assessment of adherence patterns
Gastrointestinal symptom review
Dietary habits assessment
Complete medical history to identify comorbidities

Laboratory Evaluation

Core laboratory testing includes:

TSH, free T4, and free T3 levels
Anti-thyroid antibodies (anti-TPO, anti-thyroglobulin)
Celiac disease screening (tissue transglutaminase antibodies)
H. pylori testing when indicated
Complete blood count, comprehensive metabolic panel

Specialized Testing

For selected cases:

Levothyroxine absorption test
Thyrotropin-releasing hormone (TRH) stimulation test
Genetic testing for deiodinase or thyroid receptor mutations
Gut microbiome analysis

Management Strategies

Optimizing Standard Therapy

Initial approaches include:

Improving adherence:
- Once-daily dosing
- Medication reminder systems
- Patient education on proper administration
- Consistent timing of administration
Optimizing absorption:
- Administration on empty stomach (30-60 minutes before breakfast)
- Separation from interfering medications (4-hour interval)
- Switching to liquid or soft gel LT4 formulations

Alternative Treatment Options

Combination Therapy

Addition of liothyronine (T3) to standard LT4 therapy:

Typically administered at a ratio of 10:1 to 20:1 (LT4:T3)
Particularly beneficial for patients with deiodinase defects
May improve cognitive and psychological symptoms in selected patients
Requires careful monitoring due to risk of thyrotoxicosis

Novel Formulations

Liquid levothyroxine:
- Bypasses dissolution step
- 19-31% higher bioavailability
- Less affected by food and PPI use
Soft gel capsules:
- Enhanced dissolution properties
- Improved absorption in patients with gastric pH abnormalities
- Less subject to food interaction effects
Parenteral administration:
- Weekly or biweekly intramuscular injections
- Reserved for severe malabsorption cases

Treating Underlying Conditions

Celiac disease management:
- Gluten-free diet improves LT4 absorption
- May reduce LT4 requirement by 30-50%
H. pylori eradication:
- Reduces LT4 requirements in infected patients
- Improves gastric acidity required for absorption
Correction of nutritional deficiencies:
- Selenium supplementation may enhance deiodinase activity
- Vitamin D optimization improves immune function

Emerging Approaches

Timed-release T3 formulations:
- Provides more physiological T3 delivery
- Reduces risk of T3 concentration peaks
Thyroid hormone receptor modulators:
- Selective activation of thyroid hormone receptor subtypes
- Potential benefits in tissues expressing specific receptor variants
Personalized medicine approaches:
- Genetic testing to identify specific defects
- Microbiome analysis and targeted probiotic therapy

Special Populations

Elderly Patients

Lower initial dosing and slower titration
Increased risk of cardiovascular effects with aggressive replacement
Higher prevalence of polypharmacy and drug interactions
Regular monitoring for subclinical thyrotoxicosis

Pregnant Women

Increased LT4 requirements (30-50%)
Adjustment typically needed by week 4-6 of gestation
Monthly TSH monitoring during pregnancy
Goal TSH <2.5 mIU/L in first trimester, <3.0 mIU/L in second and third trimesters

Critical Illness

Altered thyroid hormone metabolism during acute illness
Non-thyroidal illness syndrome may complicate interpretation
Consider temporary parenteral administration in severe cases

Monitoring and Follow-up

Laboratory Monitoring

TSH every 6-8 weeks during dose adjustments
Free T4 and T3 measurement in selected cases
Annual monitoring once stable

Clinical Monitoring

Symptom evaluation using standardized questionnaires
Quality of life assessment
Cardiovascular and bone health monitoring

Conclusion

Refractory hypothyroidism represents a significant clinical challenge requiring systematic evaluation and individualized management. Differentiating between true resistance and apparent resistance due to adherence or absorption issues is critical. Recent advances in understanding genetic and molecular mechanisms of thyroid hormone action have expanded therapeutic options. Combination therapy, novel formulations, and personalized approaches based on specific pathophysiological mechanisms offer promise for improved outcomes in this challenging patient population.

References

Chiovato L, Magri F, Carlé A. Hypothyroidism in context: where we've been and where we're going. Adv Ther. 2019;36(Suppl 2):47-58.
Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751.
Centanni M, Benvenga S, Sachmechi I. Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report. J Endocrinol Invest. 2017;40(12):1289-1301.
Virili C, Antonelli A, Santaguida MG, Benvenga S, Centanni M. Gastrointestinal malabsorption of thyroxine. Endocr Rev. 2019;40(1):118-136.
McMillan M, Rotenberg KS, Vora K, et al. Comorbidities, concomitant medications, and diet as factors affecting levothyroxine therapy: results of the CONTROL Surveillance Project. Drugs R D. 2016;16(1):53-68.
Guglielmi R, Grimaldi F, Negro R, et al. Shift from levothyroxine tablets to liquid formulation at breakfast improves quality of life of hypothyroid patients. Endocr Metab Immune Disord Drug Targets. 2018;18(3):235-240.
Fallahi P, Ferrari SM, Ruffilli I, et al. Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update. Expert Opin Drug Deliv. 2017;14(5):647-655.
Gonzalez-Aguilera B, Betea D, Lutteri L, Cavalier E, Geenen V, Beckers A. Conversion to soft gel capsule formulation of levothyroxine improves the management of hypothyroidism. J Endocrinol Invest. 2018;41(5):549-553.
Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009;94(5):1623-1629.
Wiersinga WM. Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism. Nat Rev Endocrinol. 2014;10(3):164-174.
Livadas S, Bothou C, Androulakis I, et al. Levothyroxine replacement therapy and overuse: a timely diagnostic approach. Thyroid. 2018;28(11):1580-1590.
Peterson SJ, Cappola AR, Castro MR, et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2018;28(6):707-721.
Hennessey JV, Espaillat R. Current evidence for the treatment of hypothyroidism with levothyroxine/liothyronine combination therapy versus levothyroxine monotherapy. Int J Clin Pract. 2018;72(2):e13062.
Virili C, Stramazzo I, Santaguida MG, Bruno G, Brusca N, Capriello S, Cellini M, Severi C, Centanni M. Ulcerative colitis as a novel cause of increased need for levothyroxine. Front Endocrinol. 2020;11:37.
Taylor PN, Iqbal A, Minassian C, et al. Falling threshold for treatment of borderline elevated thyrotropin levels—balancing benefits and risks: evidence from a large community-based study. JAMA Intern Med. 2014;174(1):32-39.
Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Individualised requirements for optimum treatment of hypothyroidism: complex needs, limited options. Drugs Context. 2019;8:212597.
Zhu X, Cheng SY. New insights into regulation of lipid metabolism by thyroid hormone. Curr Opin Endocrinol Diabetes Obes. 2010;17(5):408-413.
Benvenga S, Carlé A, Fliers E, et al. Central hypothyroidism: a neglected thyroid disorder. Front Endocrinol. 2021;12:627980.
Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017;390(10101):1550-1562.
Biondi B, Wartofsky L. Treatment with thyroid hormone. Endocr Rev. 2014;35(3):433-512.

manikath

Sunday, April 20, 2025